Here's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IRWD - Ironwood Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$3.70
DETAILS
HIGH:
$3.70
LOW:
$3.70
MEDIAN:
$3.70
CONSENSUS:
$3.70
DOWNSIDE:
3.90%
Stock News
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey Silber as his successor. Dr. Silber will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs reporting.
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4th at 11:05 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceutic.
IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Use
Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional constipation.
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living wi
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC. With thi.
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity
Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, supported by an SA Quant STRONG BUY rating and a base-case target of $6.90, implying ~100% upside. Short-term volatility is attributed to management changes and insider sales, but underlying cash generation and business model remain intact.
Ironwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is Due
Ironwood Pharmaceuticals is downgraded to Hold after the CFO's resignation and despite record Q1 2026 Linzess-driven revenues. IRWD guides for $1.125–$1.175bn in Linzess sales and $450–$475m in total revenues in 2026 but faces 2027 Medicare price cuts and 2029 generic entry. Apraglutide's Phase 3 confirmatory trial launches in 2026, but competitive and regulatory hurdles cloud its $700m peak sales potential.
Ironwood Pharmaceuticals Q1 Earnings Call Highlights
Ironwood Pharmaceuticals NASDAQ: IRWD reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory phase III program for apraglutide in short bowel syndrome with intestinal failure (SBS-IF).
Ironwood Stock Down Despite Q1 Earnings and Revenue Beat
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call Transcript
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.14 per share a year ago.
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2026 results and recent business performance. “Our first quarter of 2026 delivered strong financial performance, driven by significantly improved net price and mid-single digit prescription growth for LINZESS, positioning us well to achieve our full-y.
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, presented new findings at Digestive Diseases Week® (DDW) 2026 from a survey assessing healthcare provider (HCP) perspectives on the use of total parenteral nutrition (TPN) in the treatment of short bowel syndrome (SBS). Surveyed HCPs emphasized the importance of reducing patient dependence on TPN to improve quality of life, reduce line infections and lower the risk of thrombosis. The majority (46.4%) identified reducing the number of days per week on TPN as a priority attribute of future therapies. An additional 30.1% prioritized reducing TPN hours per day, while fewer respondents (11.3%) prioritized reducing TPN volume.
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present data from its LANDMARK survey during the 2026 Digestive Disease Week® (DDW) meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professional (HCP) insights on the burden of total parenteral nutrition (TPN) f.
Best 5 Small-Cap Stocks With Forward EPS Growth Above 125%
Small-cap stocks have outperformed amid a rotation away from mega caps, despite geopolitical uncertainty and shifting interest rate expectations. Small-cap firms may benefit from the next phase of AI adoption as productivity gains broaden across industries. Wells Fargo estimates that each 1% reduction in labor costs could translate into a 6.1% earnings increase for Russell 2000 companies.
Price Targets
Ironwood Pharmaceuticals (IRWD) PT Raised to $3.70 at Jefferies
$3.70
(was $3.60)
Amy Li
·
Jefferies
Craig-Hallum upgrades Ironwood to Buy following 2026 guidance
$5.70
(was $4.27)
Craig-Hallum
Ironwood price target raised to $5 from $3 at Wells Fargo
$5.00
(was $4.27)
Wells Fargo
Ironwood price target raised to $3.80 from $1.70 at Craig-Hallum
$3.80
(was $3.83)
Craig-Hallum
Ironwood price target lowered to $1 from $3 at Leerink
$1.00
(was $0.65)
Faisal Khurshid
·
Leerink Partners
Ironwood price target lowered to $7 from $12 at Wells Fargo
$7.00
(was $2.34)
Mohit Bansal
·
Wells Fargo
Ironwood initiated with a Market Perform at Leerink
$5.00
(was $4.51)
Faisal Khurshid
·
Leerink Partners
Ironwood price target lowered to $12 from $14 at Wells Fargo
$12.00
(was $4.05)
Mohit Bansal
·
Wells Fargo
Piper Sandler Reiterates Overweight Rating on Ironwood Pharmaceuticals (IRWD)
$18.00
(was $6.82)
David Amsellem
·
Piper Sandler
Wells Fargo Reiterates Overweight Rating on Ironwood Pharmaceuticals (IRWD)
$14.00
(was $6.78)
Mohit Bansal
·
Wells Fargo
Ironwood Pharmaceuticals (IRWD) Stock: Why The Price Increased 3.4% Today
$16.00
(was $12.18)
David Amsellem
·
Piper Sandler